Skip to main content
. 2018 Oct 5;9:2314. doi: 10.3389/fimmu.2018.02314

Figure 1.

Figure 1

The expression of NLRC5, RIG-I and MDA5 but not that of NLRX1 is upregulated by CpG-A treatment in the human GEN2.2 pDC cell line. (A–E) GEN2.2 cells were treated with increasing concentration of CpG-A (0.25–1 μM) in a time dependent manner. The expression of NLRC5 and NLRX1 was measured at the mRNA level by Q-PCR (A) and at the protein level by western blotting (B,C). The changes in protein levels of RIG-I, MDA5, MAVS, and TBK1 were also analyzed after CpG-A treatments by western blotting (D,E). Representative blots are shown in (B,D). Data are shown as mean ± SD from 4 to 6 independent experiments in panels (A,C,E). Data were analyzed using one-way ANOVA followed by Bonferroni's post-hoc test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 1 μM CpG-A vs control; +p < 0.05, ++p < 0.01, +++p < 0.001, ++++p < 0.0001 0.5 μM CpG-A vs control; #p < 0.05, ##p < 0.01, ###p < 0.001, ####p < 0.0001 0.25 μM CpG-A vs control.